Diabetes Remains a Serious Challenge for Medical Institutions

It’s unclear how the new medical legislation will directly affect medical institutions like hospitals. However, diabetes will continue to remain a serious challenge baring any comprehensive plan to address the disease. This presents several challenges and opportunities for any institution. This includes dealing with diabetes directly, dealing with it indirectly, and working to minimize cost to the institution while maximizing care for patients.

The first challenge comes from dealing with those who have diabetes directly. According to the American Diabetes Association, there are more than 1.6 million new cases of diabetes a year. Certainly, some of these cases will be caught by a patient’s regular doctor, but many people learn of diabetes from seeking emergency treatment for its symptoms without the knowledge of the illness itself. These people often require emergency treatment and it’s vitally important that one keep staff on hand that can identify and manage new cases of diabetes.

Also, it’s important to have a strong diabetes management system for any in patient care. Any institution must ensure both that regular diabetes treatment doesn’t interfere with any special inpatient treatment, and they must also make sure that the patient still receives their regular diabetes treatment. The importance of the proper management of diabetes cannot be stressed enough. Improper management of diabetes can lead to dangerous and costly complications in patient treatment.

Certainly care remains the core service provided by any medical institution, but the biggest challenge remains cost. Every service increases the cost for the institution and prevents it from offering other services. A strong diabetes management program helps protect patients, but it may ultimately reduce costs. One can spend extra to help train medical service professionals to deal with diabetes effectively which may reduces costs associated with inefficiencies of less skilled treatment. In addition, one must evaluate effectiveness of diabetes supplies when considering cost. Slightly more expensive diabetes equipment my reduce your institutions costs over time.

Enhanced by Zemanta

New Medical Technology May Reduce the Amount of Liver Biopsies

Generally speaking, identifying liver damage entailed an invasive biopsy where a piece of the liver was taken and then analyzed by a medical lab. Most liver diseases increase the complications of any surgery or biopsy further increasing the danger to the patients. Until recently, that was simply the cost of searching for liver disease. However, there are some exciting new possibilities for identification and treatment of liver disease.

Most damage to the liver creates fibrous tissues known as fibrosis. This scar tissue impairs the functioning of the heart and can ultimately lead to complications and death in some cases. However, a new technology known as a Fibroscan may allow better identification of liver damage in the future.

The Fibroscan is an ultrasound machine set to image the liver. As with all ultrasound machines, it sends out a specific carrier wave which is then slowed and reflected by the various tissue within the body. The ultrasound machine itself then processes the return signal through a complex computer algorithm to determine the exact amount of fibrous tissue by calculating the return time relative to a normal return time. This can all be done without the invasive procedures needed for a biopsy.

The Fibroscan is not yet available to wide spread use, but there are some positive signs that make it likely this will soon appear on the market. First, it’s approved and has met with general success and approval in the European Union and the United Kingdom. Secondly, it has been cleared for clinical trials within the United States. The initial results compared to traditional biopsy have been quite successful and it’s likely that we’ll soon see a wider authorization of clinical trials if not approval.

The most obvious benefit to this technology would be patient comfort. However, it has the added bonus of reducing the costs to both the hospital and the patient since they’ll be able to avoid costly biopsies in most cases.

Enhanced by Zemanta